Cameroon Achieves Milestone with Launch of World’s Inaugural Malaria Vaccine Program

Cameroon made history on Monday by initiating the world’s first routine vaccine program against malaria, a major milestone in the fight against the deadly disease. This groundbreaking effort is part of a larger initiative involving 20 African countries set to introduce the drug in the current year, as reported by the global vaccine alliance Gavi.

Key points about the vaccine program include:

The RTS,S malaria vaccine, developed by British pharmaceutical company GSK and marketed as Mosquirix, gained World Health Organisation (WHO) backing in July 2022.

The vaccine, targeting the deadliest strain of malaria, P. falciparum, underwent trials in Ghana, Kenya, and Malawi, showcasing its potential impact on the most common form of malaria in Africa.

Administered in four doses starting from approximately 5 months of age, the vaccine addresses a critical need for young children in malaria-prone regions.

The development of Mosquirix spans almost four decades, with its origins dating back to 1987.

Funding for the RTS,S-based vaccine for young children was secured by the drugmaker in 2001, paving the way for its eventual allocation of 18 million doses to 12 countries in July 2023.

Despite the vaccine’s potential, concerns have been raised:

Mosquirix demonstrated a reduction in severe malaria risk by approximately 30% in a large-scale clinical trial in 2015.

Some researchers suggest its efficacy could be higher if administered just before the malaria season.

The logistical challenges of providing at least four doses raise concerns, particularly in remote areas where fully inoculating children may be challenging.

The initiative has garnered widespread interest:

Over 30 African countries have expressed interest in adopting the vaccine, highlighting the urgency of addressing malaria in the region.

The WHO estimates a growing demand for 40-60 million doses annually by 2026, escalating to 80-100 million by 2030.

Addressing potential supply challenges:

Anticipated shortages are expected due to high demand, but the introduction of a second vaccine, R21, developed by Oxford University, could alleviate pressure.

Pre-qualified by the WHO in December, the R21 vaccine may launch as early as May or June, offering an additional tool in the fight against malaria.

As Cameroon takes this historic step, the global community watches closely, hopeful that these advancements will significantly impact malaria prevention and contribute to improved health outcomes for vulnerable populations.